DexCom (DXCM) Stock Price, News & Analysis

+3.87 (+2.89%)
(As of 05:22 PM ET)
Today's Range
50-Day Range
52-Week Range
3.24 million shs
Average Volume
2.96 million shs
Market Capitalization
$53.15 billion
P/E Ratio
Dividend Yield
Price Target

DexCom MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.93 Rating Score
2.8% Upside
$141.40 Price Target
Short Interest
3.78% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.69mentions of DexCom in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$25.53 M Sold Last Quarter
Proj. Earnings Growth
From $1.76 to $2.23 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.40 out of 5 stars

Medical Sector

105th out of 909 stocks

Surgical & Medical Instruments Industry

16th out of 96 stocks

DXCM stock logo

About DexCom Stock (NASDAQ:DXCM)

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DXCM Stock Price History

DXCM Stock News Headlines

Pentagon contract could send this $2 AI stock soaring
Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on
DexCom Stock Gains from GLP-1 Diabetic Users
DexCom Inc. NASDAQ: DXCM is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People with diabetes use CGM systems to monitor their blood glucose levels.
DexCom Stock Gains from GLP-1 Diabetic Users
DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People
DexCom (NASDAQ:DXCM) Downgraded to Hold at
Pentagon contract could send this $2 AI stock soaring
Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on
DexCom, Inc. (DXCM)
DexCom (DXCM) Set to Announce Earnings on Thursday
RBC Capital Keeps Their Buy Rating on Dexcom (DXCM)
DexCom (DXCM) Stock Moves -1.16%: What You Should Know
The Analyst Verdict: DexCom In The Eyes Of 4 Experts
See More Headlines
Receive DXCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
14 Analysts


Net Income
$541.50 million
Pretax Margin


Sales & Book Value

Annual Sales
$3.62 billion
Cash Flow
$2.17 per share
Book Value
$5.35 per share


Free Float
Market Cap
$53.15 billion

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Should I Buy DexCom Stock? DXCM Pros and Cons Explained


Here are some ways that investors could benefit from investing in DexCom, Inc.:

  • DexCom's recent growth initiatives have led to a significant increase in its total primary care prescriber base and the number of new patients starting in primary care, indicating a positive trajectory for the company.
  • The Centers for Medicare and Medicaid Services' approval of expanded coverage for CGM products to a wider group of type 2 diabetics has opened up a larger market of potential users for DexCom, including those who don't require insulin treatment and those with low blood sugar.
  • The company's innovative Dexcom G7 continuous glucose monitoring system, highlighted in a Super Bowl ad, offers a cutting-edge solution for diabetes management by eliminating the need for finger blood draws and providing real-time glucose readings directly to smartphones or smartwatches.
  • DexCom's aim to expand into additional patient markets such as Type 2 Non-Insulin, Pre-Diabetes, Gestational Diabetes, Patient Monitoring, and Health & Wellness indicates a strategic approach towards diversification and growth.
  • With DexCom shares currently in the buy range after clearing a specific buy point, there may be a favorable entry point for investors looking to capitalize on the company's potential growth.


Investors should be bearish about investing in DexCom, Inc. for these reasons:

  • Market volatility and potential pullbacks in the broader market could impact DexCom's stock price, leading to short-term fluctuations that may require cautious consideration by investors.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these DexCom pros and cons to

DXCM Stock Analysis - Frequently Asked Questions

Should I buy or sell DexCom stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DXCM shares.
View DXCM analyst ratings
or view top-rated stocks.

What is DexCom's stock price target for 2024?

14 Wall Street analysts have issued 1-year price objectives for DexCom's stock. Their DXCM share price targets range from $100.00 to $165.00. On average, they expect the company's stock price to reach $141.40 in the next twelve months. This suggests a possible upside of 2.8% from the stock's current price.
View analysts price targets for DXCM
or view top-rated stocks among Wall Street analysts.

How have DXCM shares performed in 2024?

DexCom's stock was trading at $124.09 on January 1st, 2024. Since then, DXCM stock has increased by 10.8% and is now trading at $137.51.
View the best growth stocks for 2024 here

Are investors shorting DexCom?

DexCom saw a decline in short interest in March. As of March 31st, there was short interest totaling 14,570,000 shares, a decline of 8.2% from the March 15th total of 15,870,000 shares. Based on an average trading volume of 3,090,000 shares, the days-to-cover ratio is currently 4.7 days.
View DexCom's Short Interest

When is DexCom's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our DXCM earnings forecast

How can I listen to DexCom's earnings call?

DexCom will be holding an earnings conference call on Thursday, April 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) released its quarterly earnings results on Thursday, February, 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.07. The medical device company earned $1.03 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 14.95% and a trailing twelve-month return on equity of 28.31%. The business's revenue was up 26.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.34 earnings per share.
Read the conference call transcript

When did DexCom's stock split?

DexCom shares split on the morning of Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly minted shares were issued to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What guidance has DexCom issued on next quarter's earnings?

DexCom updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $4.2 billion-$4.4 billion, compared to the consensus revenue estimate of $4.3 billion.

What is Kevin Sayer's approval rating as DexCom's CEO?

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Kevin Sayer has an approval rating of 88% among the company's employees.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

Who are DexCom's major shareholders?

DexCom's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vaughan Nelson Investment Management L.P. (0.37%), Allspring Global Investments Holdings LLC (0.33%), Congress Asset Management Co. MA (0.29%), Raymond James & Associates (0.27%), Sumitomo Mitsui Trust Holdings Inc. (0.26%) and Raymond James Financial Services Advisors Inc. (0.15%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Matthew Vincent Dolan, Michael Jon Brown, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends

How do I buy shares of DexCom?

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does DexCom have any subsidiaries?
The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.
Read More
This page (NASDAQ:DXCM) was last updated on 4/24/2024 by Staff

From Our Partners